<h2 dir="ltr">Paroxysmal Nocturnal Hemoglobinuria</h2>
<p dir="ltr">Paroxysmal Nocturnal Hemoglobinuria (PNH) is a rare acquired hematologic disorder characterized by complement-mediated destruction of red blood cells due to deficiency of GPI-anchored proteins on hematopoietic cells. The disease can lead to chronic hemolysis, thrombosis, bone marrow failure, and significant morbidity, making early diagnosis and targeted treatment critical for improving patient outcomes.</p>
<h2 dir="ltr">Paroxysmal Nocturnal Hemoglobinuria Epidemiology Segmentation</h2>
<ul>
<li dir="ltr" aria-level="1">
<p dir="ltr" role="presentation">Total Diagnosed Prevalent Cases of PNH</p>
</li>
<li dir="ltr" aria-level="1">
<p dir="ltr" role="presentation">Gender-specific Cases of PNH</p>
</li>
<li dir="ltr" aria-level="1">
<p dir="ltr" role="presentation">Age-specific Cases of PNH</p>
</li>
<li dir="ltr" aria-level="1">
<p dir="ltr" role="presentation">Total Treated Cases of PNH</p>
</li>
</ul>
<h2 dir="ltr">Paroxysmal Nocturnal Hemoglobinuria Epidemiology</h2>
<ul>
<li dir="ltr" aria-level="1">
<p dir="ltr" role="presentation">Across the 7 Major Markets (7MM), the total diagnosed prevalent population of PNH was estimated at approximately 16K cases in 2025.</p>
</li>
<li dir="ltr" aria-level="1">
<p dir="ltr" role="presentation">The United States accounted for 50% of diagnosed prevalent cases, followed by EU4 and the UK (34%) and Japan (16%).</p>
</li>
<li dir="ltr" aria-level="1">
<p dir="ltr" role="presentation">The United States accounted for the highest number of treated cases among the 7MM.</p>
</li>
<li dir="ltr" aria-level="1">
<p dir="ltr" role="presentation">Age-specific diagnosed cases of PNH in the United States were distributed as &lt;18 years (5%), 18&ndash;34 years (26%), 35&ndash;54 years (36%), 55&ndash;74 years (28%), and 75 years and above (5%).</p>
</li>
<li dir="ltr" aria-level="1">
<p dir="ltr" role="presentation">These cases across the 7MM are expected to increase with a moderate CAGR through 2036 due to improved diagnosis, increasing disease awareness, and greater availability of targeted therapies.</p>
</li>
</ul>
<h2 dir="ltr">Paroxysmal Nocturnal Hemoglobinuria Market</h2>
<ul>
<li dir="ltr" aria-level="1">
<p dir="ltr" role="presentation">Within the 7 Major Markets (7MM), the United States captured the largest share of the PNH market in 2025, accounting for approximately 63% of the total market.</p>
</li>
<li dir="ltr" aria-level="1">
<p dir="ltr" role="presentation">The PNH market size across the 7MM was estimated at approximately USD 1.5 billion in 2025.</p>
</li>
<li dir="ltr" aria-level="1">
<p dir="ltr" role="presentation">The market is projected to grow at a CAGR of 7.1% during the forecast period (2026&ndash;2036).</p>
</li>
<li dir="ltr" aria-level="1">
<p dir="ltr" role="presentation">Market growth is primarily driven by increasing awareness of PNH, supportive government initiatives, expanding research activities, and the introduction of innovative complement-targeted therapies.</p>
</li>
</ul>
<h2 dir="ltr">Paroxysmal Nocturnal Hemoglobinuria Market Drivers</h2>
<ul>
<li dir="ltr" aria-level="1">
<p dir="ltr" role="presentation">Increasing prevalence and improved diagnosis are expanding the treated patient population.</p>
</li>
<li dir="ltr" aria-level="1">
<p dir="ltr" role="presentation">Rising awareness among healthcare professionals is facilitating earlier detection and treatment initiation.</p>
</li>
<li dir="ltr" aria-level="1">
<p dir="ltr" role="presentation">Growing adoption of targeted complement inhibitors is improving disease management and outcomes.</p>
</li>
<li dir="ltr" aria-level="1">
<p dir="ltr" role="presentation">Increasing research and development activities continue to strengthen the therapeutic landscape.</p>
</li>
</ul>
<h2 dir="ltr">Paroxysmal Nocturnal Hemoglobinuria Market Barriers</h2>
<ul>
<li dir="ltr" aria-level="1">
<p dir="ltr" role="presentation">Limited therapeutic options remain a challenge despite recent advancements in complement inhibition.</p>
</li>
<li dir="ltr" aria-level="1">
<p dir="ltr" role="presentation">The complex and heterogeneous clinical presentation of PNH can delay diagnosis and treatment decisions.</p>
</li>
<li dir="ltr" aria-level="1">
<p dir="ltr" role="presentation">Persistent hemolysis, chronic anemia, transfusion dependence, and reduced quality of life may continue despite C5 inhibitor therapy.</p>
</li>
<li dir="ltr" aria-level="1">
<p dir="ltr" role="presentation">The emergence of biosimilars may create pricing pressure and affect the commercial performance of branded therapies.</p>
</li>
</ul>
<h2 dir="ltr">Emerging Paroxysmal Nocturnal Hemoglobinuria Drugs</h2>
<ul>
<li dir="ltr" aria-level="1">
<p dir="ltr" role="presentation">Danicopan</p>
</li>
<li dir="ltr" aria-level="1">
<p dir="ltr" role="presentation">Pozelimab</p>
</li>
<li dir="ltr" aria-level="1">
<p dir="ltr" role="presentation">Cemdisiran</p>
</li>
<li dir="ltr" aria-level="1">
<p dir="ltr" role="presentation">Crovalimab</p>
</li>
<li dir="ltr" aria-level="1">
<p dir="ltr" role="presentation">Iptacopan</p>
</li>
<li dir="ltr" aria-level="1">
<p dir="ltr" role="presentation">And others</p>
</li>
</ul>
<h2 dir="ltr">Key Paroxysmal Nocturnal Hemoglobinuria Companies</h2>
<ul>
<li dir="ltr" aria-level="1">
<p dir="ltr" role="presentation">AstraZeneca (Alexion Pharmaceuticals)</p>
</li>
<li dir="ltr" aria-level="1">
<p dir="ltr" role="presentation">Apellis Pharmaceuticals</p>
</li>
<li dir="ltr" aria-level="1">
<p dir="ltr" role="presentation">Novartis</p>
</li>
<li dir="ltr" aria-level="1">
<p dir="ltr" role="presentation">Hoffmann-La Roche</p>
</li>
<li dir="ltr" aria-level="1">
<p dir="ltr" role="presentation">Chugai Pharmaceutical</p>
</li>
<li dir="ltr" aria-level="1">
<p dir="ltr" role="presentation">Regeneron Pharmaceuticals</p>
</li>
<li dir="ltr" aria-level="1">
<p dir="ltr" role="presentation">Alnylam Pharmaceuticals</p>
</li>
<li dir="ltr" aria-level="1">
<p dir="ltr" role="presentation">Samsung Bioepis</p>
</li>
<li dir="ltr" aria-level="1">
<p dir="ltr" role="presentation">Teva Pharmaceuticals</p>
</li>
<li dir="ltr" aria-level="1">
<p dir="ltr" role="presentation">And others.</p>
</li>
</ul>
<p dir="ltr">&nbsp;</p>

Paroxysmal Nocturnal Hemoglobinuria Market

Paroxysmal Nocturnal Hemoglobinuria Market Infographics 

Paroxysmal Nocturnal Hemoglobinuria Symptoms, Treatment, epidemiology, companies, drugs, infographic is a short guide to understand the problem and market landscape